Atenolol thiourea hybrid as potent urease inhibitors: Design, biology-oriented drug synthesis, inhibitory activity screening, and molecular docking studies
作者:Sana Wahid、Sajid Jahangir、Muhammad Ali Versiani、Khalid Mohammed Khan、Uzma Salar、Muhammad Ashraf、Urva Farzand、Abdul Wadood、Kanwal、Ashfaq-ur-Rehaman、Arshia、Muhammad Taha、Shahnaz Perveen
DOI:10.1016/j.bioorg.2019.103359
日期:2020.1
Screening results revealed that whole library was found to be active having IC50 ranges from 11.73 ± 0.28 to 212.24 ± 0.42 µM. It is noteworthy that several derivatives including 3 (IC50 = 21.65 ± 0.31 µM), 8 (IC50 = 19.26 ± 0.42 µM), 9 (IC50 = 21.27 ± 0.25 µM), 12 (IC50 = 21.52 ± 0.42 µM), 17 (IC50 = 19.26 ± 0.42 µM), 20 (IC50 = 16.78 ± 0.34 µM), and 22 (IC50 = 11.73 ± 0.28 µM) showed excellent inhibitory
当前的研究涉及具有药理学意义的药物阿替洛尔的二十三种新硫脲类似物的面向生物学的药物合成(BIODS),阿替洛尔是治疗高血压和心血管疾病(CVD)的著名药物。所有化合物的结构表征均通过各种光谱技术完成。使化合物1-23在体外具有脲酶抑制活性。筛选结果表明,发现整个文库都具有活性,IC50范围为11.73±0.28至212.24±0.42 µM。值得注意的是,几种衍生工具包括3(IC50 = 21.65±0.31 µM),8(IC50 = 19.26±0.42 µM),9(IC50 = 21.27±0.25 µM),12(IC50 = 21.52±0.42 µM),17(IC50 = 19.26±0.42 µM),20(IC50 = 16.78±0.34 µM)和22(IC50 = 11.73±0)。28 µM的抑菌潜能优于母体阿替洛尔(IC50 = 64.36±0.19 µM)和标准硫脲(IC50